Aims: Evaluate the response of Lipodox (pegylated liposomal doxorubicin) in patients with recurrencefmetastastic ovarian carcinoma in K hospital. Results: Completed response was 15.4 percent Single substance and 34.6 percent met one part, the clinical benefit achieved 63.5 percent. The tumor pelvic peritoneum-drive had more response as compared to liver metastasis, lungs and lymph nodes. The response rate was 50.0 percent for single and 57.1 percent of 2 tumors and more. The response rate depended on the previous chemotherpay and metastatic status. Cystadenoma may have the highest response rate of 54.8 percent. Index CA-125 in blood after treatment decreases corresponding response on tumor entity. Conclusion: Monochemotherapy Lipodox is effective in patients with recurrent ovarian carcinoma after platinum treatment.
- Đăng nhập để gửi ý kiến